nab-sirolimus + marizomib

nab-sirolimus is an albumin-bound nanoparticle formulation of sirolimus, a potent inhibitor of the mechanistic target of rapamycin kinase (mTOR). This formulation, also known as ABI-009 or Fyarro, is designed to enhance tumor uptake and mTOR target suppression compared to oral mTOR inhibitors. The drug acts by inhibiting mTOR, a serine/threonine-specific protein kinase that regulates cell growth, proliferation, survival, and angiogenesis. By blocking this pathway, nab-sirolimus suppresses cytokine-driven T-cell proliferation and inhibits tumor cell growth. It has demonstrated significant clinical benefit in patients with advanced malignant perivascular epithelioid cell tumors (PEComa), leading to its approval for this indication in the United States[2][3][5][8]. Marizomib is not described in detail in the provided sources but is known as a proteasome inhibitor under investigation for various cancers.

Other names

sirolimus protein-bound particles for injectable suspensionrapamycin protein-bound nanoparticles (albumin-bound)sirolimus NAB